Novel Pharmacological Treatment Options in Pediatric Glioblastoma-A Systematic Review

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jun 10

PMID 35681794

Authors

Johanna Wyss

Nicole Alexandra Frank

Jehuda Soleman

Katrin Scheinemann

Affiliations

Soon will be listed here.

Abstract

Background: Pediatric glioblastoma (GBM) is an aggressive central nervous system tumor in children that has dismal prognosis. Standard of care is surgery with subsequent irradiation and temozolomide. We aimed to outline currently available data on novel pharmacological treatments for pediatric GBM.

Methods: We conducted a systematic literature search in PubMed and Embase, including reports published in English from 2010 to 2021. We included randomized trials, cohort studies and case series. Phase I trials were not analyzed. We followed PRISMA guidelines, assessed the quality of the eligible reports using the Newcastle-Ottawa scale (NOS) and the RoB-2 tool and registered the protocol on PROSPERO.

Results: We included 6 out of 1122 screened reports. All six selected reports were prospective, multicenter phase II trials (five single-arm and one randomized controlled trial). None of the investigated novel treatment modalities showed any benefit regarding overall or progression free survival.

Conclusions: To date, the role of pharmacological approaches regarding pediatric GBM remains unclear, since no novel treatment approach could provide a significant impact on overall or progression free survival. Further research should aim to combine different treatment strategies in large international multicenter trials with central comprehensive diagnostics regarding subgrouping. These novel treatment approaches should include targeted and immunotherapeutic treatments, potentially leading to a more successful outcome.

Citing Articles

Enhancing glioblastoma therapy: unveiling synergistic anticancer effects of Onalespib - radiotherapy combination therapy.

Uffenorde J, Hariri M, Papalanis E, Staffas A, Berg J, Stenerlow B Front Oncol. 2025; 15:1451156.

PMID: 39949745 PMC: 11821960. DOI: 10.3389/fonc.2025.1451156.

Cell Fate Dynamics Reconstruction Identifies TPT1 and PTPRZ1 Feedback Loops as Master Regulators of Differentiation in Pediatric Glioblastoma-Immune Cell Networks.

Uthamacumaran A Interdiscip Sci. 2024; 17(1):59-85.

PMID: 39420135 DOI: 10.1007/s12539-024-00657-4.

Unraveling the Landscape of Pediatric Glioblastoma Biomarkers: A Comprehensive Review of Enhancing Diagnostics and Therapeutic Insights.

Katole V, Kaple M Cureus. 2024; 16(3):e57272.

PMID: 38686271 PMC: 11057698. DOI: 10.7759/cureus.57272.

Development of Orthotopic Patient-Derived Xenograft Models of Pediatric Intracranial Tumors.

Upton D, Ziegler D, Tsoli M Methods Mol Biol. 2024; 2806:75-90.

PMID: 38676797 DOI: 10.1007/978-1-0716-3858-3_7.

The Clinical Relevance of the EPH/Ephrin Signaling Pathway in Pediatric Solid and Hematologic Malignancies.

Chatzikalil E, Stergiou I, Papadakos S, Konstantinidis I, Theocharis S Int J Mol Sci. 2024; 25(7).

PMID: 38612645 PMC: 11011407. DOI: 10.3390/ijms25073834.

References

Wolff J, Hernaiz Driever P, Erdlenbruch B, Kortmann R, Rutkowski S, Pietsch T . Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer. 2009; 116(3):705-12. DOI: 10.1002/cncr.24730. View

Drobysheva A, Klesse L, Bowers D, Rajaram V, Rakheja D, Timmons C . Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas. J Natl Compr Canc Netw. 2017; 15(8):978-982. DOI: 10.6004/jnccn.2017.0139. View

Wetmore C, Daryani V, Billups C, Boyett J, Leary S, Tanos R . Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021. Cancer Med. 2016; 5(7):1416-24. PMC: 4944867. DOI: 10.1002/cam4.713. View

Vredenburgh J, Desjardins A, Herndon 2nd J, Dowell J, Reardon D, Quinn J . Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13(4):1253-9. DOI: 10.1158/1078-0432.CCR-06-2309. View

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

Friedman G, Johnston J, Bag A, Bernstock J, Li R, Aban I . Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. N Engl J Med. 2021; 384(17):1613-1622. PMC: 8284840. DOI: 10.1056/NEJMoa2024947. View

Perkins S, Rubin J, Leonard J, Smyth M, El Naqa I, Michalski J . Glioblastoma in children: a single-institution experience. Int J Radiat Oncol Biol Phys. 2011; 80(4):1117-21. DOI: 10.1016/j.ijrobp.2010.03.013. View

Stupp R, Hegi M, Neyns B, Goldbrunner R, Schlegel U, Clement P . Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010; 28(16):2712-8. DOI: 10.1200/JCO.2009.26.6650. View

Cohen M, Shen Y, Keegan P, Pazdur R . FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009; 14(11):1131-8. DOI: 10.1634/theoncologist.2009-0121. View

10.

Fangusaro J . Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. J Child Neurol. 2009; 24(11):1409-17. DOI: 10.1177/0883073809338960. View

11.

Yamada S, Bu X, Khankaldyyan V, Gonzales-Gomez I, McComb J, Laug W . Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery. 2007; 59(6):1304-12. DOI: 10.1227/01.NEU.0000245622.70344.BE. View

12.

Panigrahy D, Kaipainen A, Butterfield C, Chaponis D, Laforme A, Folkman J . Inhibition of tumor angiogenesis by oral etoposide. Exp Ther Med. 2012; 1(5):739-746. PMC: 3445956. DOI: 10.3892/etm.2010.127. View

13.

Robison N, Campigotto F, Chi S, Manley P, Turner C, Zimmerman M . A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer. 2013; 61(4):636-42. PMC: 4285784. DOI: 10.1002/pbc.24794. View

14.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

15.

Chen C, Deshmukh S, Jessa S, Hadjadj D, Lisi V, Andrade A . Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell. 2020; 183(6):1617-1633.e22. PMC: 7791404. DOI: 10.1016/j.cell.2020.11.012. View

16.

Bouffet E, Larouche V, Campbell B, Merico D, De Borja R, Aronson M . Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. J Clin Oncol. 2016; 34(19):2206-11. DOI: 10.1200/JCO.2016.66.6552. View

17.

Toh C, Wei K, Chang C, Hsu P, Wong H, Ng S . Differentiation of pyogenic brain abscesses from necrotic glioblastomas with use of susceptibility-weighted imaging. AJNR Am J Neuroradiol. 2012; 33(8):1534-8. PMC: 7966558. DOI: 10.3174/ajnr.A2986. View

18.

Westerdijk K, Desar I, Steeghs N, van der Graaf W, van Erp N . Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose. Br J Clin Pharmacol. 2019; 86(2):258-273. PMC: 7015742. DOI: 10.1111/bcp.14185. View

19.

Gorsi H, Malicki D, Barsan V, Tumblin M, Yeh-Nayre L, Milburn M . Nivolumab in the Treatment of Recurrent or Refractory Pediatric Brain Tumors: A Single Institutional Experience. J Pediatr Hematol Oncol. 2019; 41(4):e235-e241. DOI: 10.1097/MPH.0000000000001339. View

20.

Su J, Li X, Thompson P, Ou C, Ingle A, Russell H . Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin Cancer Res. 2010; 17(3):589-97. PMC: 3064523. DOI: 10.1158/1078-0432.CCR-10-0738. View